Psoriasis trials recruiting in Ohio

All Psoriasis trials nationally

Cities in Ohio

Recruiting trials in Ohio

• A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
  NCT07013201 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Mayfield Heights
• A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
  NCT07250802 · Phase: Phase 3 · Ages: 4 Years to 17 Years · Sex: All (male and female) · Ohio: Canton, Fairborn, Mayfield Heights
• A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
  NCT06663332 · Phase: Phase 3 · Ages: 3 Years and older · Sex: All (male and female) · Ohio: Cincinnati
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
  NCT06671483 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland, Middleburg Heights
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
  NCT06671496 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland, Middleburg Heights
• A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
  NCT06100744 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · Ohio: Cleveland
• A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
  NCT07489885 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Ohio: Mayfield Heights
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
  NCT07219420 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus, Fairborn, Mayfield Heights
• A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
  NCT07321873 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Middleburg Heights
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
  NCT06979453 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Ohio: Canton, Lorain, Mayfield Heights
• A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
  NCT06454188 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Middleburg Heights
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Boardman
• A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
  NCT07290036 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Vandalia
• Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
  NCT07286058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Middleburg Heights
• Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
  NCT05270733 · Phase: Phase 4 · Ages: 18 Years to 89 Years · Sex: All (male and female) · Ohio: Cleveland
• Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
  NCT07474792 · Phase: Phase 2 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Ohio: Bexley
• Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
  NCT06641089 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Middleburg Heights
• Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
  NCT05669833 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Ohio: Blue Ash, Wheelersburg
• IMPACT - AndHealth Autoimmune Research Registry
  NCT05883371 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: All (male and female) · Ohio: Columbus
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
  NCT07116967 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · Ohio: Bexley, Canal Winchester, Canton, Fairborn
• Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors
  NCT06399432 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 94 Years · Sex: All (male and female) · Ohio: Cleveland
• Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
  NCT02418442 · Phase: Not specified · Ages: Up to 21 Years · Sex: All (male and female) · Ohio: Akron, Cincinnati, Cleveland, Columbus
• Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
  NCT06865105 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Middleburg Heights
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
  NCT04036188 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Fairborn